Psychedelics in Cluster Headaches Are Breaking the Pain Cycle

Cluster headaches are anecdotally among the most painful conditions humans experience. Cluster headaches are often referred to as a “suicide headache” because 47% to 55% of patients with this disorder reported suicidal thoughts.¹ Additionally, those who experience cluster headaches are approximately 5.6 times more likely to be depressed.² This debilitating primary headache disorder is characterized by multiple paroxysmal attacks in the orbital or periorbital areas. Individual attacks can last 15 to 180 minutes and may occur up to 8 times per day.³

Cluster headaches can present as episodic (attack periods lasting weeks to months) or chronic (year-round attacks without a headache-free period > 3 months). Adequate treatment is vital to patient well-being, as the severity of this disorder can significantly impact quality of life.

Current Recommended Treatment

Current pharmacologic options for managing cluster headaches are separated into symptomatic/abortive therapy or preventive therapy.⁴ Symptomatic or abortive therapy aims to stop acute attacks and may include high-flow oxygen therapy, triptans (eg, sumatriptan or zolmitriptan), and ergotamine derivatives, which are rarely used because of adverse effects (AEs). Ketamine therapy has strong preliminary evidence but lacks controlled trials that determine its efficacy.

Preventive therapy aims to prevent future attacks and may include verapamil, lithium, topiramate, and calcitonin gene–related peptide antagonists (eg, galcanezumab).

Pharmacologic treatment is limited by medication interactions, AEs, and inefficacy, with 10% to 20% of those with chronic cluster headaches being refractory to treatment. As a result, there is a call to action for new, novel therapies in this population.

Psychedelic Research in Cluster Headaches

Emerging evidence exists for the use of psychedelics in cluster headaches; however, the use of psychedelics for headache treatment is not new, with the first investigation conducted more than 60 years ago.³ The most researched agents are psilocybin and lysergic acid diethylamide (LSD), which primarily act through agonism of the 5-hydroxytryptamine 2A receptor. Although psychedelics are known to cause alterations in sensation, perception, and mood, research shows that therapeutic microdoses have efficacy in preventing cluster headaches without significant hallucinogenic AEs.

A 2006 Harvard survey/narrative review studied the response of psilocybin and LSD on patients with cluster headaches and found that approximately 52% of those using psilocybin and 88% of those using LSD experienced periods of remission⁵; however, the findings of this observational study highlight the need for more controlled data.

Recent controlled trials have begun to address this gap. In 2024, a US-based randomized controlled trial examined the effect of a psilocybin pulse regimen on cluster headache attack frequency in the blinded extension phase.⁶ The 10 enrolled patients in this trial received 3 doses of psilocybin 10 mg/70 kg every 5 days and an additional pulse 6 months after the first regimen. Researchers found cluster headache attack frequency was significantly reduced by approximately 50%. Participants with chronic cluster headaches experienced a sustained reduction in frequency over 8 weeks.⁶

A separate Denmark-based randomized controlled trial published in 2024 studied a psilocybin pulse regimen in cluster headaches and demonstrated similar efficacy.⁷ Patients received a psilocybin dose of 0.14 mg/kg every 4 to 7 days for 3 doses. The authors found a statistically significant reduction of approximately 31% in cluster headache frequency, with only 1 patient experiencing 21 weeks of complete remission. Although small, the results of these randomized controlled trials demonstrate potential treatment options for patients with cluster headaches.⁷

In addition to psilocybin, research on LSD is evolving. In a Swiss case series involving 9 patients with cluster headaches, 6 experienced cessation of attacks after treatment with LSD or psilocybin.⁸ Both psychedelics were well tolerated with no significant AEs. Despite the limited generalizability of this case series, 2 ongoing clinical trials are studying LSD in this population.¹ With larger predicted sample sizes in these trials, these studies have the potential to generate more robust data for the use of psychedelics in this debilitating condition.

Access, Advocacy, and Awareness

Federal regulations in the US limit psychedelic accessibility, despite preliminary research demonstrating efficacy. Currently, Oregon, Colorado, and New Mexico are the only 3 states in the US with legalized, medical-assisted psilocybin access.⁹ As new psychedelic research continues to emerge, advocacy is vital for patients with cluster headaches to ensure access to these treatment options.

Cluster headaches are poorly understood, often leading to misdiagnosis and poor quality of life. Nonprofit organizations, such as Clusterbusters, are pillars of advocacy, especially in psychedelic medicine access.¹⁰ Through these organizations, patients with cluster headaches and their support networks can find community, seek resources for medication access, and stay informed on new research. By increasing awareness, supporting research, and advocating for compassionate care, health care providers can expand treatment conversations, providing a better quality of life for those living with cluster headaches.

REFERENCES

1. Im JJH, Sandoe CH. Psychedelics and headache disorders: an update. Curr Neurol Neurosci Rep. 2025;25(1):57. doi:10.1007/s11910-025-01446-2

2. Cheema S, Matharu M. Cluster headache: what’s new? Neurol India. 2021;69(suppl):S124-S134. doi:10.4103/0028-3886.315983

3. Shirane RA, Gottschalk C, Schindler EAD, et al. Headache horizons: the study and use of psychedelics in cluster headache. Practical Neurology. August 7, 2023. Accessed March 13, 2026. https://practicalneurology.com/diseases-diagnoses/headache-pain/headache-horizons-the-study-and-use-of-psychedelics-in-cluster-headache/32032/

4. Lansbergen CS, Fronczek R, Wilbrink LA, Cohen SP, de Vos CC, Huygen FJPM. Cluster headache. Pain Pract. 2025;25(5):e70050. doi:10.1111/papr.70050

5. Sewell RA, Halpern JH, Pope HG Jr. Response of cluster headache to psilocybin and LSD. Neurology. 2006;66(12):1920-1922. doi:10.1212/01.wnl.0000219761.05466.43

6. Schindler EAD, Sewell RA, Gottschalk CH, et al. Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. J Neurol Sci. 2024;460:122993. doi:10.1016/j.jns.2024.122993

7. Madsen MK, Petersen AS, Stenbaek DS, et al. CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity. Headache. 2024;64(1):55-67. doi:10.1111/head.14656

8. Leighton J, Lau C, Savdo A, Granata L. Clinical treatment of cluster headache with the serotonergic indoleamine psychedelics psilocybin and LSD and with ketamine: a case series. Cephalalgia Rep. Published online May 29, 2025. doi:10.1177/25158163251345472

9. Psychedelic law and policy map. University of California, Berkeley Center for the Science of Psychedelics. Updated February 2026. Accessed March 13, 2026. https://psychedelics.berkeley.edu/law-and-policy-map/

10. Clusterbusters. Accessed March 13, 2026. https://clusterbusters.org